In the pharmaceutical industry, protein kinases have become key targets for therapy of various diseases, especially in oncology. New developments in inhibiting the catalytic function of kinases, as well as emerging promising technologies, expand the possibilities of kinases for drug development. Enabling rational drug design, furthering target identification, developing selective and also multitargeted kinase inhibitors are only a few of the pharmaceutical drug development strategies. Due to the growing research and emerging technology available, the limiting factor is not the amount of data that can be obtained but rather the quality of the data, validation and the associated costs.